JP2014507475A5 - - Google Patents

Download PDF

Info

Publication number
JP2014507475A5
JP2014507475A5 JP2013557811A JP2013557811A JP2014507475A5 JP 2014507475 A5 JP2014507475 A5 JP 2014507475A5 JP 2013557811 A JP2013557811 A JP 2013557811A JP 2013557811 A JP2013557811 A JP 2013557811A JP 2014507475 A5 JP2014507475 A5 JP 2014507475A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
administered
cyclobenzaprine
composition according
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013557811A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014507475A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/027926 external-priority patent/WO2012122193A1/en
Publication of JP2014507475A publication Critical patent/JP2014507475A/ja
Publication of JP2014507475A5 publication Critical patent/JP2014507475A5/ja
Pending legal-status Critical Current

Links

JP2013557811A 2011-03-07 2012-03-06 シクロベンザプリンを使用してうつ病を処置するための方法および組成物 Pending JP2014507475A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161449838P 2011-03-07 2011-03-07
US61/449,838 2011-03-07
PCT/US2012/027926 WO2012122193A1 (en) 2011-03-07 2012-03-06 Methods and compositions for treating depression using cyclobenzaprine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016007041A Division JP2016053095A (ja) 2011-03-07 2016-01-18 シクロベンザプリンを使用してうつ病を処置するための方法および組成物

Publications (2)

Publication Number Publication Date
JP2014507475A JP2014507475A (ja) 2014-03-27
JP2014507475A5 true JP2014507475A5 (enExample) 2015-04-23

Family

ID=46796107

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013557811A Pending JP2014507475A (ja) 2011-03-07 2012-03-06 シクロベンザプリンを使用してうつ病を処置するための方法および組成物
JP2016007041A Pending JP2016053095A (ja) 2011-03-07 2016-01-18 シクロベンザプリンを使用してうつ病を処置するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016007041A Pending JP2016053095A (ja) 2011-03-07 2016-01-18 シクロベンザプリンを使用してうつ病を処置するための方法および組成物

Country Status (18)

Country Link
US (1) US11998516B2 (enExample)
EP (2) EP3682885A1 (enExample)
JP (2) JP2014507475A (enExample)
AU (4) AU2012225548B2 (enExample)
CA (1) CA2829200C (enExample)
CY (1) CY1122998T1 (enExample)
DK (1) DK2683245T4 (enExample)
ES (1) ES2773834T5 (enExample)
FI (1) FI2683245T4 (enExample)
HR (1) HRP20200142T4 (enExample)
HU (1) HUE048596T2 (enExample)
LT (1) LT2683245T (enExample)
PL (1) PL2683245T5 (enExample)
PT (1) PT2683245T (enExample)
RS (1) RS60240B2 (enExample)
SI (1) SI2683245T2 (enExample)
SM (1) SMT202000083T1 (enExample)
WO (1) WO2012122193A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011062614A1 (en) * 2009-11-20 2011-05-26 Tonix Pharmaceuticals, Inc. Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
US9636408B2 (en) 2013-03-15 2017-05-02 Tonix Pharma Holdings Limited Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
WO2015150948A1 (en) * 2014-03-29 2015-10-08 Wockhardt Limited Modified release solid oral pharmaceutical compositions of cyclobenzaprine or a salt thereof
SG10201902203VA (en) 2014-09-18 2019-04-29 Tonix Pharma Holdings Ltd Eutectic formulations of cyclobenzaprine hydrochloride
CN106890129A (zh) * 2015-12-18 2017-06-27 健乔信元医药生技股份有限公司 环苄普林之延释剂型
CA3083341C (en) * 2017-12-11 2024-05-28 Tonix Pharma Holdings Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3882246A (en) 1971-05-21 1975-05-06 Merck & Co Inc Treatment of skeletal muscle disorders with cyclobenzaprine
US4968507A (en) 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
FR2635461B1 (fr) 1988-08-18 1992-01-17 Adir Utilisation de derives tricycliques pour l'obtention de medicaments destines au traitement du stress
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
SG47101A1 (en) 1992-07-31 1998-03-20 Us Bioscience Crystalline amifostine compositions and methods for the preparation and use of same
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5498421A (en) 1993-02-22 1996-03-12 Vivorx Pharmaceuticals, Inc. Composition useful for in vivo delivery of biologics and methods employing same
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5354566A (en) 1993-06-02 1994-10-11 Kraft General Foods, Inc. Preparation of yeast-leavened dough crusts
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US6649186B1 (en) 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
WO1999018937A1 (en) 1997-10-16 1999-04-22 Merck & Co., Inc. New cyclobenzaprine composition
DE69904465T2 (de) 1998-05-14 2003-10-02 Alza Corp., Mountain View Therapie von depressionen
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
JP2003506484A (ja) * 1999-08-13 2003-02-18 ベラ・ファーマシューティカルズ・インコーポレイテッド 非常に低用量のシクロベンザプリンを使用する睡眠障害の処置または予防するための組成物使用
MXPA02001568A (es) * 1999-08-13 2002-07-02 Vela Pharmaceuticals Inc Ciclobenzaprina para tratar trastornos de ansiedad generalizada y composiciones de la misma.
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
AU2001261744A1 (en) 2000-05-19 2001-12-03 Npd Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
EP1441708B1 (en) 2001-11-05 2009-04-08 Krele Pharmaceuticals LLC Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
US7659253B2 (en) 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
US7700561B2 (en) 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
US7105486B2 (en) 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
WO2004039320A2 (en) 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. STEREOISOMERS OF p-HYDROXY-MILNACIPRAN, AND METHODS OF USE THEREOF
LT1585548T (lt) 2002-12-09 2018-09-25 Abraxis Bioscience, Llc Farmakologinių agentų kompozicijos ir įvedimo būdai
US8688385B2 (en) 2003-02-20 2014-04-01 Mayo Foundation For Medical Education And Research Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
US20050059656A1 (en) 2003-04-07 2005-03-17 Cornell Research Foundation, Inc. Compositions and methods for protecting against mitochondria component-mediated pathology
NZ544162A (en) 2003-05-29 2008-09-26 Shire Llc Abuse resistant amphetamine compounds
EP1685115A1 (en) 2003-11-03 2006-08-02 Warner-Lambert Company LLC Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
US20050143350A1 (en) 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
JP2007516259A (ja) 2003-12-09 2007-06-21 メッドクリスタルフォームズ、エルエルシー 活性剤との混合相共結晶の調製方法
KR20140104986A (ko) 2004-02-17 2014-08-29 트랜스셉트 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의 사용 방법
TW200531680A (en) 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7532935B2 (en) 2005-07-29 2009-05-12 Cyberonics, Inc. Selective neurostimulation for treating mood disorders
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20090069267A1 (en) 2006-01-17 2009-03-12 Abrams Daniel J Central administration of stable formulations of therapeutic agents for cns conditions
US20080146672A1 (en) 2006-12-08 2008-06-19 Denton Marcia Marye Topical Eutectic Anesthetic Composition for Oral or Dermal Tissue
AU2008248382B2 (en) 2007-05-07 2013-07-18 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
WO2009002770A1 (en) 2007-06-22 2008-12-31 Merck & Co., Inc. 6.5-pyrrolopiperidine tachykinin receptor antagonists
MX2010000937A (es) 2007-07-23 2010-06-25 Synosia Therapeutics Inc Tratamiento del trastorno por estrés postraumático.
US20090060983A1 (en) 2007-08-30 2009-03-05 Bunick Frank J Method And Composition For Making An Orally Disintegrating Dosage Form
HRP20191104T1 (hr) 2007-09-25 2019-09-20 Solubest Ltd. Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu
EP2203158A4 (en) 2007-10-30 2012-12-26 Reddys Lab Ltd Dr PHARMACEUTICAL FORMULATIONS WITH TELMISARTAN AND HYDROCHLORTHIAZIDE
US20090148532A1 (en) 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms
EP3090743A1 (en) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
JP5737949B2 (ja) 2008-02-08 2015-06-17 キューピーエス リミテッド ライアビリティ カンパニー 薬物制御送達用の非ポリマー組成物
US9314469B2 (en) 2008-05-05 2016-04-19 Tonix Pharma Holdings Limited Method for treating neurocognitive dysfunction
JP5380909B2 (ja) 2008-05-30 2014-01-08 株式会社ブリヂストン 金型及び樹脂発泡成形品の成形方法
US20100266682A1 (en) 2008-12-10 2010-10-21 Nipun Davar Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same
US20100247586A1 (en) 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
EP2233134A1 (en) 2009-03-27 2010-09-29 McNeil AB Multi-portion intra-oral dosage form with organoleptic properties
US8871263B2 (en) 2009-09-24 2014-10-28 Mcneil-Ppc, Inc. Manufacture of tablet in a die utilizing radiofrequency energy and meltable binder
WO2011062614A1 (en) 2009-11-20 2011-05-26 Tonix Pharmaceuticals, Inc. Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
WO2012050594A1 (en) 2010-09-01 2012-04-19 Tonix Pharmaceuticals, Inc. Treatment for cocaine addiction
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
ITMI20110558A1 (it) 2011-04-06 2012-10-07 Campiglio Consulting Srl Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale
ES2929133T3 (es) 2012-06-15 2022-11-25 Tonix Pharma Holdings Ltd Composiciones y métodos para la absorción transmucosa
EP2914585B1 (en) 2012-11-05 2018-03-07 Emory University 7,8-dihydroxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
US9636408B2 (en) 2013-03-15 2017-05-02 Tonix Pharma Holdings Limited Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
EP3177286A4 (en) 2014-07-18 2018-05-16 Medipath Inc. Compositions and methods for physiological delivery using cannabidiol
SG10201902203VA (en) 2014-09-18 2019-04-29 Tonix Pharma Holdings Ltd Eutectic formulations of cyclobenzaprine hydrochloride
CA3083341C (en) 2017-12-11 2024-05-28 Tonix Pharma Holdings Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
US20230414536A1 (en) 2022-06-21 2023-12-28 Tonix Pharmaceuticals Holding Corp. CYCLOBENZAPRINE TREATMENT FOR POST-ACUTE SEQUELAE OF (SARS)-CoV-2 INFECTION (PASC)

Similar Documents

Publication Publication Date Title
JP2014507475A5 (enExample)
JP2012193216A5 (enExample)
JP2015523407A5 (enExample)
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
HRP20150644T1 (hr) Metoda za lijeäśenje atrijalne fibrilacije
JP2013231087A5 (enExample)
JP2017506624A5 (enExample)
JP2015038135A5 (enExample)
JP2014198723A5 (enExample)
JP2010525050A5 (enExample)
JP2015057451A5 (enExample)
JP2013541583A5 (enExample)
JP2015522630A5 (enExample)
JP2018530578A5 (enExample)
JP2012533565A5 (enExample)
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
AR056824A1 (es) Tableta de neramexano con matriz de liberacion modificada
JP2016530291A5 (enExample)
JP2017533220A5 (enExample)
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害(adhd)の治療方法
JP2021509395A5 (enExample)
FI2683245T4 (fi) Menetelmiä ja koostumuksia masennuksen hoitamiseen syklobentsapriiniä käyttämällä
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
JP2018521007A5 (enExample)
PH12015500653A1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof